TNGX - Tango Therapeutics, Inc.

QQQ $ 461.58 $ 2.44 (0.53 %)

DIA $ 409.11 $ -2.23 (-0.54 %)

SPY $ 550.18 $ -0.82 (-0.15 %)

TLT $ 99.47 $ 0.15 (0.15 %)

GLD $ 232.43 $ -0.31 (-0.13 %)

Previous Close

$ 10.84

Open

$ 11.01

Bid

$ 11.46 x 100

Ask

$ 11.65 x 600

Day's Range

$ 10.65 - $ 11.48

52 Week Range

$ 5.15 - $ 13.03

Volume

258,060

Average Volume

Market Cap

1.16B

Beta (5Y Monthly)

$ 0.86

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-07-2024	06-30-2024	10-Q
2	05-08-2024	03-31-2024	10-Q
3	03-18-2024	12-31-2023	10-K
4	11-08-2023	09-30-2023	10-Q
5	08-07-2023	06-30-2023	10-Q
6	05-09-2023	03-31-2023	10-Q
7	03-27-2023	12-31-2022	10-K
8	11-10-2022	09-30-2022	10-Q
9	08-10-2022	06-30-2022	10-Q
10	05-11-2022	03-31-2022	10-Q
11	03-28-2022	12-31-2021	10-K
12	11-09-2021	09-30-2021	10-Q
13	08-09-2021	06-30-2021	10-Q
14	05-14-2021	03-31-2021	10-Q
15	03-31-2021	12-31-2020	10-K
16	11-13-2020	09-30-2020	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Analyst Expectations For Tango Therapeutic...
08/08/2024 14:00:49

Wedbush Maintains Outperform on Tango Ther...
08/08/2024 13:31:20

Wedbush analyst Robert Driscoll maintains Tango Therapeutics (NASDAQ:TNGX) with a Outperform and raises the price target fro...

Tango Therapeutics shares are trading high...
08/07/2024 13:06:10

Tango Therapeutics' Cash Balance Of $322M ...
08/07/2024 11:26:20

Tango Therapeutics Q2 2024 GAAP EPS $(0.24...
08/07/2024 11:25:29

Jefferies Initiates Coverage On Tango Ther...
07/17/2024 12:45:41

Jefferies analyst Maury Raycroft initiates coverage on Tango Therapeutics (NASDAQ:TNGX) with a Buy rating and announces Pric...

Cantor Fitzgerald Reiterates Overweight on...
07/09/2024 13:18:53

Cantor Fitzgerald analyst Eric Schmidt reiterates Tango Therapeutics (NASDAQ:TNGX) with a Overweight.

Expert Outlook: Tango Therapeutics Through...
07/09/2024 13:00:12

HC Wainwright & Co. Reiterates Buy on Tang...
07/09/2024 10:43:12

HC Wainwright & Co. analyst Robert Burns reiterates Tango Therapeutics (NASDAQ:TNGX) with a Buy and maintains $13 price ...

CORRECTION: Tectonic Therapeutic Ticker Is...
06/26/2024 19:04:33

HC Wainwright & Co. Maintains Buy on Tango...
05/28/2024 10:41:16

HC Wainwright & Co. analyst Robert Burns maintains Tango Therapeutics (NASDAQ:TNGX) with a Buy and lowers the price targ...

Guggenheim Maintains Buy on Tango Therapeu...
05/24/2024 16:31:14

Guggenheim analyst Charles Zhu maintains Tango Therapeutics (NASDAQ:TNGX) with a Buy and lowers the price target from $16 to...

Forecasting The Future: 4 Analyst Projecti...
05/24/2024 15:01:25

Barclays Maintains Overweight on Tango The...
05/24/2024 14:56:22

Barclays analyst Peter Lawson maintains Tango Therapeutics (NASDAQ:TNGX) with a Overweight and lowers the price target from ...

tango-therapeutics-shuts-early-stage-cancer-study-due-to-liver-toxicity

Tango Therapeutics Shuts Early-Stage Cance...
05/23/2024 16:53:11

Tango Therapeutics halts its TNG348 program due to liver toxicity issues found in dose escalation studies. The company will now...

Wedbush Maintains Outperform on Tango Ther...
05/23/2024 16:35:58

Wedbush analyst Robert Driscoll maintains Tango Therapeutics (NASDAQ:TNGX) with a Outperform and lowers the price target fro...

12-health-care-stocks-moving-in-thursdays-pre-market-session

12 Health Care Stocks Moving In Thursday's...
05/23/2024 12:06:48

Tango Therapeutics shares are trading lowe...
05/23/2024 11:02:42

Tango Therapeutics Reports Discontinuation...
05/23/2024 11:01:44

TNG348 was being studied in a phase 1/2 clinical trial evaluating safety, pharmacokinetics, pharmacodynamics and efficacy as a ...

HC Wainwright & Co. Reiterates Buy on Tang...
05/09/2024 11:16:18

HC Wainwright & Co. analyst Robert Burns reiterates Tango Therapeutics (NASDAQ:TNGX) with a Buy and maintains $17 price ...